No headlines found.
Business Wire (Thu, 5-Mar 7:30 AM ET)
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics PLC - American Depository Share trades on the NASDAQ stock market under the symbol SLN.
As of April 2, 2026, SLN stock price climbed to $5.77 with 139,623 million shares trading.
SLN has a beta of 1.48, meaning it tends to be more sensitive to market movements. SLN has a correlation of 0.08 to the broad based SPY ETF.
SLN has a market cap of $272.43 million. This is considered a Small Cap stock.
Last quarter Silence Therapeutics PLC - American Depository Share reported $34,000 in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-7 million and exceeded earnings estimates by $.16.
In the last 3 years, SLN traded as high as $27.72 and as low as $1.97.
The top ETF exchange traded funds that SLN belongs to (by Net Assets): IBB, GWX, IBBQ, BIB.
SLN has outperformed the market in the last year with a return of +138.4%, while the SPY ETF gained +17.7%. However, in the most recent history, SLN shares have underperformed the stock market with its stock returning -5.1% in the last 3 month period and -13.0% for the last 2 week period, while SPY has returned -4.0% and -1.0%, respectively.
SLN support price is $5.04 and resistance is $5.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLN shares will trade within this expected range on the day.
